Search
SLAM family member 7; CD2 subset 1; CD2-like receptor-activating cytotoxic cells; CRACC; membrane protein FOAP-12; Novel Ly9; protein 19A; signaling lymphocytic activation molecule F7; CD319 (SLAMF7, CS1, UNQ576/PRO1138)
Function:
- isoform 1 mediates NK cell activation through a SH2D1A- independent extracellular signal-regulated ERK-mediated pathway
- may play a role in lymphocyte adhesion
- isoform 3 does not mediate any NK cell activation
- isoform 1 binds to SH2D1A when its cytoplasmic tail is phosphorylated in the presence of FYN (in vitro)
Structure:
- contains 1 Ig-like C2-type domain
Compartment:
- membrane; single-pass type 1 membrane protein
Alternative splicing: named isoforms=3
Expression:
- expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung & trachea
- expressed in NK cells, activated B-cells, NK-cell line
- not expressed in promyelocytes, B-cell lines, or T-cell lines
- isoform 3 is expressed at much lower level than isoform 1
Pharmacology:
- immunostimulatory monoclonal antibody elotuzumab (Empliciti) directed against SLAMF7 is FDA-approved to treat relapsed or refractory multiple myeloma [2]
General
cluster-of-differentiation antigen; cluster designation antigen; CD antigen
glycoprotein
SLAM family member protein
Properties
SIZE: entity length = 335 aa
MW = 37 kD
COMPARTMENT: cellular membrane
MOTIF: signal sequence {1-22}
N-glycosylation site {N98}
immunoglobulin superfamily domain {131-206}
MOTIF: N-glycosylation site {N142}
cysteine residue {C145}
MODIFICATION: cysteine residue {C215}
N-glycosylation site {N148}
cysteine residue {C151}
MODIFICATION: cysteine residue {C195}
N-glycosylation site {N172}
N-glycosylation site {N176}
cysteine residue {C195}
MODIFICATION: cysteine residue {C151}
N-glycosylation site {N204}
cysteine residue {C215}
MODIFICATION: cysteine residue {C145}
transmembrane domain {227-247}
Database Correlations
OMIM 606625
UniProt Q9NQ25
Pfam PF07686
Entrez Gene 57823
Kegg hsa:57823
References
- Uniprot Q9NQ25
- Lonial S, Dimopoulos M, Palumbo A et al
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2015 Aug 13;373(7):621-31..
PMID: 26035255